search
Back to results

Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr) (TaxEr)

Primary Purpose

Antioxidative Stress, Cold, Influenza

Status
Active
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Taxifolin
Ergothioneine
Control
Sponsored by
University of Southampton
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Antioxidative Stress focused on measuring Phagocytosis, Immunosenecence, Cytokine, Antioxidant, Metabolome, Microbiome

Eligibility Criteria

50 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • age 50-65yr
  • BMI 18.5-30kg/m2
  • Willing to avoid consumption of foods rich in Taxifolin/DHQ and Ergothioneine during the study period
  • Willing to avoid taking any other food supplements or high doses of vitamins during the study period
  • Able to provide written informed consent.

Exclusion Criteria:

  • Use of prescription medication which may influence immune function, such as anti-inflammatory or immunosuppressant medication
  • Diabetes requiring any medication
  • Liver cirrhosis
  • A history of drug or alcohol misuse
  • Asplenia or other acquired or congenital immunodeficiencies
  • Any autoimmune disease including connective tissue diseases
  • Malignancy
  • Laboratory confirmed SARS-CoV-2 infection within last 3 months
  • self-reported symptoms of acute or recent infection (including use of antibiotics within the last 3 months)

Sites / Locations

  • NIHR Southampton Biomedical Research Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Taxifolin/Dihydroquercetin

Ergothioneine

Control

Arm Description

250mg/day Taxifolin (also known as Dihydroquercetin). One capsule in the morning for 8 weeks.

80mg/day Ergothioneine. One capsule in the morning for 8 weeks.

One capsule in the morning for 8 weeks.

Outcomes

Primary Outcome Measures

Phagocytosis activity by granulocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.

Secondary Outcome Measures

Percentage phagocytosis by monocytes ex vivo
Percentage of cells undergoing phagocytosis will be assessed by flow cytometry.
Phagocytosis activity by monocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Percentage phagocytosis by granulocytes ex vivo
Percentage of cells undergoing phagocytosis will be assessed by flow cytometry.
Phagocytosis activity by granulocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Percentage oxidative burst by monocytes ex vivo
Percentage of cells undergoing oxidative burst will be assessed by flow cytometry.
Oxidative burst activity by monocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Percentage oxidative burst by granulocytes ex vivo
Percentage of cells undergoing oxidative burst will be assessed by flow cytometry.
Oxidative burst activity by granulocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Frequencies of naive T cells
The proportion of naive T cells will be assessed by flow cytometry.
Frequencies of memory T cells
The proportion of memory T cells will be assessed by flow cytometry.
CD57 expression upon T cells.
The proportion of T cells expressing CD57 (a marker associated with chronic immune activation) and the mean fluorescence intensity per cell will be assessed by flow cytometry.
CD28 expression upon T cells.
The proportion of T cells expressing CD28 (a cell surface marker required for T cell activation and survival) and the mean fluorescence intensity per cell will be assessed by flow cytometry.
Plasma lipid peroxides
Participant plasma lipid peroxides will be measured by colorimetric analysis.
Urinary isoprostanes
Participant urinary isoprostanes will be measured by commercially available ELISA.
Plasma isoprostanes
Participant plasma isoprostanes will be measured by commercially available ELISA.
Cytokine production by cryopreserved peripheral blood mononuclear cells in response to lipopolyssaccharide
A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array.
Cytokine production by cryopreserved peripheral blood mononuclear cells in response to influenza or coronavirus vaccine products
A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array.
Metabolomic analysis of urine samples
Full metabolic profiling of first-morning urine samples will be used to assess changes to metabolic activity of participants and their microbiome.
Metabolomic analysis of serum samples
Full metabolic profiling of serum samples will be used to assess changes to metabolic activity of participants.
Faecal microbiome analysis
Sequences of ribosomal RNA (rRNA) in participant faecal samples will be measured to assess changes in the numbers or proportions of bacterial genera and species/strains.
Incidence of self-reported seasonal cold, coronavirus and influenza-like illness.
A daily online form will be completed by participants to log any seasonal cold, coronavirus and influenza-like illness.
Duration of self-reported illness.
A daily online form will be completed by participants to log any self-reported illness.
Severity of self-reported illness.
A daily online form will be completed by participants to log any self-reported illness.
Self-reported medication use.
A daily online form will be completed by participants to log any medication use.

Full Information

First Posted
December 22, 2020
Last Updated
May 31, 2023
Sponsor
University of Southampton
Collaborators
Blue California
search

1. Study Identification

Unique Protocol Identification Number
NCT05190432
Brief Title
Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr)
Acronym
TaxEr
Official Title
A Pilot Study of Dietary Taxifolin/Dihydroquercetin and Ergothioneine and Immune Biomarkers in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 10, 2021 (Actual)
Primary Completion Date
September 29, 2022 (Actual)
Study Completion Date
November 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Southampton
Collaborators
Blue California

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The complexities of the immune system make measuring the impact of dietary interventions upon its function challenging. The immune system is highly responsive to environmental influences, including the diet. An individual's diet provides the energy required to mount a strong and protective immune response, the building blocks required for synthesis of immune mediators such as antibodies and cytokines, and can also indirectly affect immune function via changes in the gut microbiome. Immune function varies across the lifecourse, with a well understood decline in immune function with age, resulting in impaired vaccination responses and an increased risk of infections and of severe complications and mortality arising from common communicable diseases such as influenza. This impaired immunity with ageing is known as immunosenescence and this affects both innate and acquired arms of the immune system.
Detailed Description
Expert guidance is available to inform the design of human nutrition trials to ensure they include the most relevant immunological outcomes (Albers, 2013). In this study, ex vivo phagocytosis and oxidative burst of immune cells will be the primary outcome, supported by other ex vivo immune measures of high clinical relevance including functional assessment of cytokine production and expression of activation markers. Human nutritional trials frequently omit to monitor the degree of immunosenescence in participants, even amongst studies conducted amongst older adults. For example, a recent review of pre- and probiotic trials which assessed immune responses in older adults identified that only two of thirty-six studies assessed any marker of immunosenescence (Childs & Calder, 2017). Taxifolin/DHQ is a naturally occurring polyphenol found in apples, onions and other fruits and bark extracts. Ergothioneine is an amino acid found in mushrooms, oats and some bean varieties. We hypothesise that Taxifolin/DHQ and/or Ergothioneine will alter immune function via their established antioxidant effects, and that the effects observed will vary between older adults relative to their degree of immunosenescence. Though current dietary guidelines advise consumption of 5 portions of fruits and vegetables per day, recent surveys reveal that fewer than 30% of adults achieve this. Antioxidants found within fruits and vegetables are understood to be one of the important aspects by which our diet can influence health. It is important to investigate the effects of such antioxidants through well designed and conducted human trials.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Antioxidative Stress, Cold, Influenza, Aging, Inflammation
Keywords
Phagocytosis, Immunosenecence, Cytokine, Antioxidant, Metabolome, Microbiome

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A n=90 study (3 treatment arms, each n=30) providing participants with either 250mg/day Taxifolin/DHQ, 80mg/day Ergothioneine, or control.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Alphabetically labelled treatments, with de-blinding envelope held by an independent researcher at the University of Southampton.
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Taxifolin/Dihydroquercetin
Arm Type
Experimental
Arm Description
250mg/day Taxifolin (also known as Dihydroquercetin). One capsule in the morning for 8 weeks.
Arm Title
Ergothioneine
Arm Type
Experimental
Arm Description
80mg/day Ergothioneine. One capsule in the morning for 8 weeks.
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
One capsule in the morning for 8 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Taxifolin
Other Intervention Name(s)
Dihydroquercetin
Intervention Description
A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
Intervention Type
Dietary Supplement
Intervention Name(s)
Ergothioneine
Intervention Description
An amino acid found in mushrooms, oats and some bean varieties.
Intervention Type
Dietary Supplement
Intervention Name(s)
Control
Intervention Description
Microcrystalline cellulose.
Primary Outcome Measure Information:
Title
Phagocytosis activity by granulocytes ex vivo
Description
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time Frame
8 weeks post intervention
Secondary Outcome Measure Information:
Title
Percentage phagocytosis by monocytes ex vivo
Description
Percentage of cells undergoing phagocytosis will be assessed by flow cytometry.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Phagocytosis activity by monocytes ex vivo
Description
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Percentage phagocytosis by granulocytes ex vivo
Description
Percentage of cells undergoing phagocytosis will be assessed by flow cytometry.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Phagocytosis activity by granulocytes ex vivo
Description
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time Frame
4 weeks, 3 months post intervention
Title
Percentage oxidative burst by monocytes ex vivo
Description
Percentage of cells undergoing oxidative burst will be assessed by flow cytometry.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Oxidative burst activity by monocytes ex vivo
Description
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Percentage oxidative burst by granulocytes ex vivo
Description
Percentage of cells undergoing oxidative burst will be assessed by flow cytometry.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Oxidative burst activity by granulocytes ex vivo
Description
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Frequencies of naive T cells
Description
The proportion of naive T cells will be assessed by flow cytometry.
Time Frame
8 weeks
Title
Frequencies of memory T cells
Description
The proportion of memory T cells will be assessed by flow cytometry.
Time Frame
8 weeks
Title
CD57 expression upon T cells.
Description
The proportion of T cells expressing CD57 (a marker associated with chronic immune activation) and the mean fluorescence intensity per cell will be assessed by flow cytometry.
Time Frame
8 weeks
Title
CD28 expression upon T cells.
Description
The proportion of T cells expressing CD28 (a cell surface marker required for T cell activation and survival) and the mean fluorescence intensity per cell will be assessed by flow cytometry.
Time Frame
8 weeks
Title
Plasma lipid peroxides
Description
Participant plasma lipid peroxides will be measured by colorimetric analysis.
Time Frame
8 weeks
Title
Urinary isoprostanes
Description
Participant urinary isoprostanes will be measured by commercially available ELISA.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Plasma isoprostanes
Description
Participant plasma isoprostanes will be measured by commercially available ELISA.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Cytokine production by cryopreserved peripheral blood mononuclear cells in response to lipopolyssaccharide
Description
A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array.
Time Frame
4 weeks, 8 weeks
Title
Cytokine production by cryopreserved peripheral blood mononuclear cells in response to influenza or coronavirus vaccine products
Description
A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array.
Time Frame
4 weeks, 8 weeks
Title
Metabolomic analysis of urine samples
Description
Full metabolic profiling of first-morning urine samples will be used to assess changes to metabolic activity of participants and their microbiome.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Metabolomic analysis of serum samples
Description
Full metabolic profiling of serum samples will be used to assess changes to metabolic activity of participants.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Faecal microbiome analysis
Description
Sequences of ribosomal RNA (rRNA) in participant faecal samples will be measured to assess changes in the numbers or proportions of bacterial genera and species/strains.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Incidence of self-reported seasonal cold, coronavirus and influenza-like illness.
Description
A daily online form will be completed by participants to log any seasonal cold, coronavirus and influenza-like illness.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Duration of self-reported illness.
Description
A daily online form will be completed by participants to log any self-reported illness.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Severity of self-reported illness.
Description
A daily online form will be completed by participants to log any self-reported illness.
Time Frame
4 weeks, 8 weeks, 3 months post intervention
Title
Self-reported medication use.
Description
A daily online form will be completed by participants to log any medication use.
Time Frame
4 weeks, 8 weeks, 3 months post intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: age 50-65yr BMI 18.5-30kg/m2 Willing to avoid consumption of foods rich in Taxifolin/DHQ and Ergothioneine during the study period Willing to avoid taking any other food supplements or high doses of vitamins during the study period Able to provide written informed consent. Exclusion Criteria: Use of prescription medication which may influence immune function, such as anti-inflammatory or immunosuppressant medication Diabetes requiring any medication Liver cirrhosis A history of drug or alcohol misuse Asplenia or other acquired or congenital immunodeficiencies Any autoimmune disease including connective tissue diseases Malignancy Laboratory confirmed SARS-CoV-2 infection within last 3 months self-reported symptoms of acute or recent infection (including use of antibiotics within the last 3 months)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Caroline E Childs, PhD
Organizational Affiliation
University of Southampton
Official's Role
Principal Investigator
Facility Information:
Facility Name
NIHR Southampton Biomedical Research Centre
City
Southampton
State/Province
Hampshire
ZIP/Postal Code
SO16 6YD
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23902657
Citation
Albers R, Bourdet-Sicard R, Braun D, Calder PC, Herz U, Lambert C, Lenoir-Wijnkoop I, Meheust A, Ouwehand A, Phothirath P, Sako T, Salminen S, Siemensma A, van Loveren H, Sack U. Monitoring immune modulation by nutrition in the general population: identifying and substantiating effects on human health. Br J Nutr. 2013 Aug;110 Suppl 2:S1-30. doi: 10.1017/S0007114513001505.
Results Reference
background
Citation
Childs, C. E., & Calder, P. C. (2017). Modifying the gut microbiome through diet: effects on the immune system of elderly subjects. In T. Fulop, C. Franceschi, K. Hirokawa, & G. Pawelec (Eds.), Handbook of Immunosenescence Cham: Springer International Publishing AG. DOI: 10.1007/978-3-319-64597-1_160-1
Results Reference
background
PubMed Identifier
32625400
Citation
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhauser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjodin A, Stern M, Tome D, Vinceti M, Willatts P, Engel KH, Marchelli R, Poting A, Poulsen M, Schlatter J, Gelbmann W, Van Loveren H. Scientific Opinion on taxifolin-rich extract from Dahurian Larch (Larix gmelinii). EFSA J. 2017 Feb 14;15(2):e04682. doi: 10.2903/j.efsa.2017.4682. eCollection 2017 Feb.
Results Reference
background
PubMed Identifier
32625352
Citation
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhauser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjodin A, Stern M, Tome D, Vinceti M, Willatts P, Engel KH, Marchelli R, Poting A, Poulsen M, Schlatter JR, Ackerl R, van Loveren H. Statement on the safety of synthetic l-ergothioneine as a novel food - supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women. EFSA J. 2017 Nov 13;15(11):e05060. doi: 10.2903/j.efsa.2017.5060. eCollection 2017 Nov.
Results Reference
background
PubMed Identifier
19267323
Citation
Vega-Villa KR, Remsberg CM, Ohgami Y, Yanez JA, Takemoto JK, Andrews PK, Davies NM. Stereospecific high-performance liquid chromatography of taxifolin, applications in pharmacokinetics, and determination in tu fu ling (Rhizoma smilacis glabrae) and apple (Malus x domestica). Biomed Chromatogr. 2009 Jun;23(6):638-46. doi: 10.1002/bmc.1165.
Results Reference
background
PubMed Identifier
17616140
Citation
Ey J, Schomig E, Taubert D. Dietary sources and antioxidant effects of ergothioneine. J Agric Food Chem. 2007 Aug 8;55(16):6466-74. doi: 10.1021/jf071328f. Epub 2007 Jul 6.
Results Reference
background
PubMed Identifier
26985232
Citation
Przemska-Kosicka A, Childs CE, Enani S, Maidens C, Dong H, Dayel IB, Tuohy K, Todd S, Gosney MA, Yaqoob P. Effect of a synbiotic on the response to seasonal influenza vaccination is strongly influenced by degree of immunosenescence. Immun Ageing. 2016 Mar 15;13:6. doi: 10.1186/s12979-016-0061-4. eCollection 2016.
Results Reference
background
PubMed Identifier
18345348
Citation
Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train. 2008 Apr-Jun;43(2):215-21. doi: 10.4085/1062-6050-43.2.215.
Results Reference
background
PubMed Identifier
4597226
Citation
Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974 May;15(5):443-53. doi: 10.1002/cpt1974155443. No abstract available.
Results Reference
background

Learn more about this trial

Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr)

We'll reach out to this number within 24 hrs